OpenEvidence Stock
Private company — OpenEvidence is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$613.00 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 22 June 2026
Valuation: $15.1B
Source: D, January 2026 — post-money $12B
Total raised: $735M+
Data last updated: 6 August 2026
About OpenEvidence
ChatGPT for doctors — the #1 AI clinical-decision-support platform in the US. 740K physicians (45% of all US doctors), 10,000+ clinics, and 100M+ patients reached. Monetized through targeted pharma advertising (CPM $70–150+).
OpenEvidence is the fastest-growing AI clinical-decision-support service in the US and the most-used medical search engine among physicians: 740,000 doctors (45% of all US physicians) across 10,000+ clinics. ARR grew from $7M to $150M over 2025. It monetizes through targeted pharma advertising with $1B+ in inventory. Founder Daniel Nadler previously built Kensho (sold to S&P Global for $550M).
- Sector: AI Healthcare
- Headquarters: Miami, FL, USA
- Founded: 2022
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 21 January 2026 | D | $487.38 | $12B |
| 20 October 2025 | C2 | $252.32 | $6B |
| 15 July 2025 | B1 | $150.87 | $3.5B |
| 19 February 2025 | A | $43.04 | $1B |
| 7 June 2024 | Seed4 | $28.92 | $618M |
| 31 July 2023 | Seed2 | $28.92 | $560M |
| 15 July 2022 | Seed3 | $23.14 | $425M |
| 1 November 2021 | Founder1 | $11.42 | $222M |
Latest news
- OneOncology integrated OpenEvidence into the clinical processes of its oncologists — 6 August 2026
- Springer Nature opened OpenEvidence access to its peer-reviewed medical publications — 5 August 2026
- A study found a common flaw in clinical AIs OpenEvidence, OpenAI, and Anthropic — 29 July 2026
- OpenEvidence is discussing a $200 million round at a $20 billion valuation — 17 July 2026
- OpenEvidence and Boston Children's will study the impact of AI on clinical care — 16 July 2026
- OpenEvidence launches EvidenceGrade and expands its NewYork-Presbyterian partnership — 10 July 2026
Frequently asked questions
Can I buy OpenEvidence stock?
Not on a public exchange — OpenEvidence is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
How much is one OpenEvidence share?
A private company has no single official price. AXEVIL's consensus estimate is $613.00 per share as of 22 June 2026. Its most recent round implied a post-money valuation of $12B (January 2026).
When will OpenEvidence IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is OpenEvidence publicly traded?
No. OpenEvidence is a private company and its shares are not listed on any public exchange.
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.